Shares of Becton, Dickinson and Company BDX, popularly known as BD, have gained 25.5% over the past six months, while its industry has advanced 17.6%. The stock's upward momentum is supported by improved execution after BD’s portfolio realignment, strength in high-growth businesses, and continued product innovation and clinical progress. Stronger shareholder returns and a new U.S. manufacturing agreement have further reinforced the investment case.
BDX is also scheduled to report fourth-quarter fiscal 2026 results on Nov. 5. The company is expected to beat on earnings with an Earnings ESP of 0.21%. Its earnings per share (EPS) estimate suggests 2.5% year-over-year growth despite a projected 13% decline in sales.
Image Source: Zacks Investment Research
Factors Supporting BDX’s Rally
A Focused Portfolio and Improving Earnings Visibility: BD’s third-quarter fiscal 2026 results provided fundamental support for the stock’s upward momentum.In its first full quarter of operations as “New BD” following the separation of its Life Sciences business, the company reported revenues of $5 billion, up 4.4%, while adjusted EPS of $3.23 surpassed expectations.
More than 90% of its portfolio delivered high-single-digit growth, while biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration recorded double-digit growth.
The diversified portfolio matters because the company is increasingly relying on platforms operating in faster-growing markets rather than depending solely on mature medical supplies. Management raised its full-year adjusted EPS guidance to $12.62-$12.72, increasing the midpoint, while anticipating revenue growth near the upper end of its low-single-digit projection.
Year-to-date free cash flow reached $1.7 billion, up 45%, enabling BD to return approximately $3.1 billion to shareholders through repurchases and dividends. Improving execution, stronger earnings visibility and capital returns likely supported investor confidence.
Product Innovation Expands Commercial Opportunities: BD’s commercial initiatives have broadened the potential growth contribution from its portfolio. In May, the Wellstar Health System partnership linked Pyxis Pro dispensing technology with Alaris infusion systems, advancing connected medication management. Later that month, BD introduced the Elyra Thulium Fiber Laser System, expanding its urology portfolio.
In June, the CentroVena One insertion system received a Vizient Innovative Technology contract, potentially improving access to hospitals through a major purchasing network. In July, BD and EMS launched a semaglutide therapy in Brazil using BD’s Vystra injection pen, linking BD’s drug-delivery technology with expanding GLP-1 demand.
In September, BD reached a commercialization milestone when Fairview Health Services became the first U.S. health system to deploy its Vmax 160 pharmacy automation robot. Together, these developments support a more diversified growth narrative across drug delivery, procedural care and automation.
Clinical Progress and U.S. Manufacturing Strengthen the Outlook: BD also advanced its longer-term innovation pipeline. In August, enrollment was completed in the PREVENT trial, which evaluates Phasix Mesh for incisional hernia prevention. Later that month, the STANCE trial reached its first enrollment milestone for the GalaFLEX LITE scaffold, triggering an interim analysis. These milestones expand the evidence base for advanced tissue regeneration, although clinical and commercial outcomes are yet to be established.
In October, BD announced a major partnership with the U.S. government, outlining $19 billion in planned domestic investments over several years, including $3 billion toward manufacturing expansion. The agreement also offers potential relief from certain future Section 232 tariffs, contingent on implementation and the achievement of specified milestones. The following day, positive nine-month results from the AGILITY trial of the Revello vascular covered stent provided further clinical support for BD’s peripheral vascular pipeline. Together, these manufacturing and clinical developments could strengthen the company’s long-term growth prospects.
Concerns for BDX
Despite the positive momentum, BD continues to face execution risks and macroeconomic challenges. Management noted that tariff-related costs weighed on third-quarter adjusted operating margin by approximately 130 basis points, while expenses associated with resin, plastics and freight could remain volatile. Alaris remediation remains a defined drag, with a roughly 200-basis-point revenue headwind expected in fiscal 2027. Vaccine weakness in China persists, and several tissue-regeneration or vascular opportunities still depend on trial follow-up, regulatory pathways and commercial adoption.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company price-consensus-chart | Becton, Dickinson and Company Quote
Conclusion
BD’s rally reflects a more focused portfolio, improving execution and growing commercial validation across drug delivery, automation and interventional care. The U.S. manufacturing agreement and clinical milestones extend that growth narrative. Sustaining the advance, however, will require BD to scale its growth platforms while productivity, pricing and favorable product mix help offset legacy business pressures and tariffs.
Zacks Rank & Other Key Picks
BD currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks from the broader medical space are Glaukos GKOS, Edward Lifesciences EW and Globus Medical GMED, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Glaukos Corporation (GKOS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).